Sign in Subscribe

immunotherapy

A collection of 61 issues

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to

Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. If you have BRAF

Adding immunotherapy to chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Adding immunotherapy to chemotherapy before surgery in stage III colon cancer — Clinical Colorectal Cancer The AZUR-4 trial is a Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in previously untreated T4N0 or stage III mismatch repair proficient/

Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1

Skip to content The CRC Digest Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1 Analysis of 217 patients with dMMR/MSI-H colorectal cancer found that stage III/IV tumors had reduced immune infiltration and upregulated epithelial IDO1 expression compared to stage I/II, suggesting immune evasion

Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer

Skip to content The CRC Digest Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy.

Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer

Skip to content The CRC Digest Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences) This content is informational only and does not constitute medical

CRC Research Finding

Skip to content The CRC Digest ◇ Review highlights gut microbiota's role in immunotherapy response, especially for MSI-H tumors A comprehensive review evaluates how gut microbiota and microbial metabolites influence colorectal cancer development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for proficient mismatch repair/microsatellite-stable tumors

CRC Research Finding

Skip to content The CRC Digest Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease) This content is informational only and does not constitute medical advice. Always consult your oncologist or

CRC Research Finding

Skip to content The CRC Digest ◇ Mismatch repair-deficient CRC with bowel obstruction shows excellent response to immunotherapy A case series reports that patients with mismatch repair-deficient (dMMR) colorectal cancer presenting with bowel obstruction achieved excellent responses to immunotherapy. (Annals of Coloproctology) This content is informational only and does not constitute

Immunotherapy Shows Response in Pediatric CMMRD-Associated CRC

Skip to content The CRC Digest Immunotherapy Shows Response in Pediatric CMMRD-Associated CRC A 10-year-old with constitutional mismatch repair deficiency-associated colorectal adenocarcinoma received neoadjuvant ipilimumab and nivolumab, achieving partial response. (Journal of Pediatric Hematology/Oncology) This content is informational only and does not constitute medical advice. Always consult your oncologist